candesartan cilexetil has been researched along with Hyperplasia in 4 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The AACHEN trial was a double-blind, randomized, placebo-controlled clinical multicenter trial to evaluate the effects of candesartan cilexetil on intimal hyperplasia after coronary stent implantation." | 9.12 | A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. ( Büttner, HJ; Daniel, W; Drexler, H; Figulla, HR; Fischer, D; Hanrath, P; Hoffmann, R; Klues, HG; Motz, W; Mügge, A; Ortlepp, JR; Radke, PW; Reifart, N; Schaefers, K; Schmeisser, A; Silber, S, 2006) |
| "Candesartan cilexetil treatment reduced neointimal formation both in allografts (Qint 30." | 5.31 | Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. ( Fellström, B; Larsson, E; Zezina, L, 2001) |
| " The AACHEN trial was a double-blind, randomized, placebo-controlled clinical multicenter trial to evaluate the effects of candesartan cilexetil on intimal hyperplasia after coronary stent implantation." | 5.12 | A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. ( Büttner, HJ; Daniel, W; Drexler, H; Figulla, HR; Fischer, D; Hanrath, P; Hoffmann, R; Klues, HG; Motz, W; Mügge, A; Ortlepp, JR; Radke, PW; Reifart, N; Schaefers, K; Schmeisser, A; Silber, S, 2006) |
| "Candesartan cilexetil treatment reduced neointimal formation both in allografts (Qint 30." | 1.31 | Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. ( Fellström, B; Larsson, E; Zezina, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Radke, PW | 1 |
| Figulla, HR | 1 |
| Drexler, H | 1 |
| Klues, HG | 1 |
| Mügge, A | 1 |
| Silber, S | 1 |
| Daniel, W | 1 |
| Schmeisser, A | 1 |
| Reifart, N | 1 |
| Motz, W | 1 |
| Büttner, HJ | 1 |
| Fischer, D | 1 |
| Ortlepp, JR | 1 |
| Schaefers, K | 1 |
| Hoffmann, R | 1 |
| Hanrath, P | 1 |
| Furukawa, Y | 1 |
| Matsumori, A | 1 |
| Hirozane, T | 1 |
| Sasayama, S | 1 |
| Miyazaki, M | 1 |
| Wada, T | 1 |
| Shiota, N | 1 |
| Takai, S | 1 |
| Zezina, L | 1 |
| Larsson, E | 1 |
| Fellström, B | 1 |
1 trial available for candesartan cilexetil and Hyperplasia
| Article | Year |
|---|---|
A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Coronary Angiogra | 2006 |
3 other studies available for candesartan cilexetil and Hyperplasia
| Article | Year |
|---|---|
Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Benzimidazoles; Biphenyl Com | 1999 |
Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dru | 2001 |